Item 9 Labs (INLB) Stock Price

Item 9 Labs Price

OTC·CLOSED
0.00USD+0.00 (+0.00 %)
Market closed

Revenue has compounded at 37.7% per year over the past 10 years to 21.76 M USD. Item 9 Labs's net margin stands at -143.1%, down from -49.1% several years earlier. Analysts set a median price target of 4.08 USD, implying 4,079,900.1% above the current price. Of 6 analysts, 0 rate the stock a buy — an overall Sell consensus.

Item 9 Labs stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Item 9 Labs over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Item 9 Labs stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Item 9 Labs's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Item 9 Labs Stock Price History
DateItem 9 Labs Price
8/24/20260.00 USD
8/21/20260.00 USD
8/20/20260.00 USD
8/19/20260.00 USD
8/18/20260.00 USD
8/17/20260.00 USD
8/14/20260.00 USD
8/13/20260.00 USD
8/12/20260.00 USD
8/11/20260.00 USD
8/10/20260.00 USD
8/7/20260.00 USD
8/6/20260.00 USD
8/5/20260.00 USD
8/4/20260.00 USD
8/3/20260.00 USD
7/30/20260.00 USD
7/29/20260.00 USD
7/28/20260.00 USD
7/27/20260.00 USD
7/24/20260.00 USD
7/23/20260.00 USD
7/22/20260.00 USD
7/21/20260.00 USD
7/20/20260.00 USD
7/17/20260.00 USD
7/16/20260.00 USD
7/15/20260.00 USD
7/14/20260.00 USD
7/13/20260.00 USD
7/10/20260.00 USD
7/9/20260.00 USD
7/8/20260.00 USD
7/7/20260.00 USD
7/6/20260.00 USD
7/2/20260.00 USD
7/1/20260.00 USD
6/30/20260.00 USD
6/29/20260.00 USD
6/26/20260.00 USD
6/25/20260.00 USD
6/24/20260.00 USD
6/23/20260.00 USD
6/22/20260.00 USD
6/18/20260.00 USD
6/17/20260.00 USD
6/16/20260.00 USD
6/15/20260.00 USD
6/12/20260.00 USD
6/11/20260.00 USD
6/10/20260.00 USD
6/9/20260.00 USD
6/8/20260.00 USD
6/5/20260.00 USD
6/4/20260.00 USD
6/3/20260.00 USD
6/2/20260.00 USD
6/1/20260.00 USD
5/29/20260.00 USD
5/28/20260.00 USD
5/27/20260.00 USD
5/26/20260.00 USD
5/22/20260.00 USD
5/21/20260.00 USD
5/20/20260.00 USD
5/19/20260.00 USD
5/18/20260.00 USD
5/15/20260.00 USD
5/14/20260.00 USD
5/13/20260.00 USD
5/12/20260.00 USD
5/11/20260.00 USD
5/8/20260.00 USD
5/7/20260.00 USD
5/6/20260.00 USD
5/5/20260.00 USD
5/4/20260.00 USD
5/1/20260.00 USD
4/30/20260.00 USD
4/29/20260.00 USD
4/28/20260.00 USD
4/27/20260.00 USD
4/24/20260.00 USD
4/23/20260.00 USD
4/22/20260.00 USD
4/21/20260.00 USD
4/20/20260.00 USD
4/17/20260.00 USD
4/16/20260.00 USD
4/15/20260.00 USD
4/14/20260.00 USD
4/13/20260.00 USD
4/10/20260.00 USD
4/9/20260.00 USD
4/8/20260.00 USD
4/7/20260.00 USD
4/6/20260.00 USD
4/2/20260.00 USD
4/1/20260.00 USD
3/31/20260.00 USD
3/30/20260.00 USD
3/27/20260.00 USD
3/26/20260.00 USD
3/25/20260.00 USD
3/24/20260.00 USD
3/23/20260.00 USD
3/20/20260.00 USD
3/19/20260.00 USD
3/18/20260.00 USD
3/17/20260.00 USD
3/16/20260.00 USD
3/13/20260.00 USD
3/12/20260.00 USD
3/11/20260.00 USD
3/10/20260.00 USD
3/9/20260.00 USD
3/6/20260.00 USD
3/5/20260.00 USD
3/4/20260.00 USD
3/3/20260.00 USD
3/2/20260.00 USD
2/27/20260.00 USD
2/26/20260.00 USD
2/25/20260.00 USD
2/24/20260.00 USD
2/23/20260.00 USD
2/20/20260.00 USD
2/19/20260.00 USD
2/18/20260.00 USD
2/17/20260.00 USD
2/13/20260.00 USD
2/12/20260.00 USD
2/11/20260.00 USD
2/10/20260.00 USD
2/9/20260.00 USD
2/6/20260.00 USD
2/5/20260.00 USD
2/4/20260.00 USD
2/3/20260.00 USD
2/2/20260.00 USD
1/30/20260.00 USD
1/29/20260.00 USD
1/28/20260.00 USD
1/27/20260.00 USD
1/26/20260.00 USD
1/23/20260.00 USD
1/22/20260.00 USD
1/21/20260.00 USD
1/20/20260.00 USD
1/16/20260.00 USD
1/15/20260.00 USD
1/14/20260.00 USD
1/13/20260.00 USD
1/12/20260.00 USD
1/9/20260.00 USD
1/8/20260.00 USD
1/7/20260.00 USD
1/6/20260.00 USD
1/5/20260.00 USD
1/2/20260.00 USD
12/31/20250.00 USD
12/30/20250.00 USD
12/29/20250.00 USD
12/26/20250.00 USD
12/24/20250.00 USD
12/23/20250.00 USD
12/22/20250.00 USD
12/19/20250.00 USD
12/18/20250.00 USD
12/17/20250.00 USD
12/16/20250.00 USD
12/15/20250.00 USD
12/12/20250.00 USD
12/11/20250.00 USD
12/10/20250.00 USD
12/9/20250.00 USD
12/8/20250.00 USD
12/5/20250.00 USD
12/4/20250.00 USD
12/3/20250.00 USD
12/2/20250.00 USD
12/1/20250.00 USD
11/28/20250.00 USD
11/26/20250.00 USD
11/25/20250.00 USD
11/24/20250.00 USD
11/21/20250.00 USD
11/20/20250.00 USD
11/19/20250.00 USD
11/18/20250.00 USD
11/17/20250.00 USD
11/14/20250.00 USD
11/13/20250.00 USD
11/12/20250.00 USD
11/11/20250.00 USD
11/10/20250.00 USD
11/7/20250.00 USD
11/6/20250.00 USD
11/5/20250.00 USD
11/4/20250.00 USD
11/3/20250.00 USD
10/31/20250.00 USD
10/30/20250.00 USD
10/29/20250.00 USD
10/28/20250.00 USD
10/27/20250.00 USD
10/24/20250.00 USD
10/23/20250.00 USD
10/22/20250.00 USD
10/21/20250.00 USD
10/20/20250.00 USD
10/17/20250.00 USD
10/16/20250.00 USD
10/15/20250.00 USD
10/14/20250.00 USD
10/13/20250.00 USD
10/10/20250.00 USD
10/9/20250.00 USD
10/8/20250.00 USD
10/7/20250.00 USD
10/6/20250.00 USD
10/3/20250.00 USD
10/2/20250.00 USD
10/1/20250.00 USD
9/30/20250.00 USD
9/29/20250.00 USD
9/26/20250.00 USD
9/25/20250.00 USD
9/24/20250.00 USD
9/23/20250.00 USD
9/22/20250.00 USD
9/19/20250.00 USD
9/18/20250.00 USD
9/17/20250.00 USD
9/16/20250.00 USD
9/15/20250.00 USD
9/12/20250.00 USD
9/11/20250.00 USD
9/10/20250.00 USD
9/9/20250.00 USD
9/8/20250.00 USD
9/5/20250.00 USD
9/4/20250.00 USD
9/3/20250.00 USD
9/2/20250.00 USD
8/29/20250.00 USD
8/28/20250.00 USD
8/27/20250.00 USD
8/26/20250.00 USD
Access this data via the Eulerpool API
Get Free API Key

Item 9 Labs Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
1.40 M USD
-653,800.00 USD
-688,700.00 USD
Jan 1, 2019
4.93 M USD
-4.38 M USD
-9.82 M USD
Jan 1, 2020
8.12 M USD
-5.33 M USD
-12.27 M USD
Jan 1, 2021
21.94 M USD
-5.60 M USD
-10.91 M USD
Jan 1, 2022
21.76 M USD
-13.12 M USD
-31.14 M USD
Jan 1, 2023 (e)
23.97 M USD
-4.75 M USD
-12.69 M USD
Jan 1, 2024 (e)
30.60 M USD
-2.45 M USD
-7.81 M USD
Jan 1, 2025 (e)
111.67 M USD
96.88 M USD
0.00 USD

Item 9 Labs Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 26, 2026, 3:08 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201020112012201320142015201820192020202120222023e2024e2025e
––––––1.004.008.0021.0021.0023.0030.00111.00
–––––––300.00100.00162.50–9.5230.43270.00
––––––700.0050.0037.5038.1033.3333.3333.3333.33
7.007.007.007.007.007.007.002.003.008.007.007.6710.0037.00
––-3.00-1.00-1.00-1.00–-4.00-5.00-5.00-13.00-4.00-2.0096.00
–––––––-100.00-62.50-23.81-61.90-17.39-6.6786.49
––-4.00-3.00-17.00-4.00–-9.00-12.00-10.00-31.00-12.00-7.00–
–––-25.00466.67-76.47––33.33-16.67210.00-61.29-41.67–
0.450.521.251.722.493.3254.7761.5361.6278.5995.6995.6995.6995.69
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Item 9 Labs generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Item 9 Labs retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Item 9 Labs's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Item 9 Labs has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Item 9 Labs's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Item 9 Labs stock margins

The Item 9 Labs margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Item 9 Labs. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Item 9 Labs.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
27.38 %
-46.64 %
-49.13 %
Jan 1, 2019
48.19 %
-88.82 %
-199.12 %
Jan 1, 2020
40.58 %
-65.58 %
-151.12 %
Jan 1, 2021
39.26 %
-25.53 %
-49.71 %
Jan 1, 2022
33.61 %
-60.30 %
-143.14 %
Jan 1, 2023 (e)
33.61 %
-19.83 %
-52.93 %
Jan 1, 2024 (e)
33.61 %
-8.00 %
-25.52 %
Jan 1, 2025 (e)
33.61 %
86.75 %
0.00 %

Item 9 Labs Stock Revenue, EBIT, Earnings per Share

The Item 9 Labs earnings per share therefore indicates how much revenue Item 9 Labs has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
0.03 USD
-0.01 USD
-0.01 USD
Jan 1, 2019
0.08 USD
-0.07 USD
-0.16 USD
Jan 1, 2020
0.13 USD
-0.09 USD
-0.20 USD
Jan 1, 2021
0.28 USD
-0.07 USD
-0.14 USD
Jan 1, 2022
0.23 USD
-0.14 USD
-0.33 USD
Jan 1, 2023 (e)
0.25 USD
-0.05 USD
-0.13 USD
Jan 1, 2024 (e)
0.32 USD
-0.03 USD
-0.08 USD
Jan 1, 2025 (e)
1.17 USD
1.01 USD
0.00 USD

Item 9 Labs business model & stock analysis

Item 9 Labs Corp was founded in 2014 and is headquartered in Arizona, USA. As an innovative manufacturer of cannabis products, the company aims to revolutionize the industry and change the way the world views and uses cannabis. The business model of Item 9 Labs Corp focuses on developing and producing high-quality cannabis products. The company specializes in producing high-quality cannabinoid extracts for medical and recreational purposes. Item 9 Labs Corp's products are distributed by a network of retailers in Arizona and other states. Item 9 Labs Corp specializes in various sectors to meet the needs of customers in different areas. These sectors include the production of medical cannabis products, recreational cannabis products, and technological services for cannabis plant cultivation. Item 9 Labs Corp's medical cannabis products are tailored to the needs of patients affected by various health issues. These include products for pain relief, treating sleep disorders, anxiety and panic attacks, as well as treating nausea and other symptoms associated with different diseases. Item 9 Labs Corp's recreational products are designed for people who want to use cannabis for leisure activities. The company offers a wide range of products, ranging from traditional flowers to various concentrates and vapes. The company also has a division for technological services that focuses on optimal cannabis plant cultivation. Innovative and resource-saving methods are used to achieve optimal results. Item 9 Labs Corp aims to revolutionize the cannabis industry and find innovative ways to improve plant cultivation. To provide customers with the best products and services, Item 9 Labs Corp places great emphasis on quality and durability in the production of its product range. The company is known for using only the highest quality materials and conducting strict quality controls. The company has also built partnerships with retailers to ensure its products are available throughout Arizona. The company strives to develop new and innovative products that meet customer needs. This includes products that are tailored to the requirements of customers seeking a specific effect or experience, as well as products designed for specific symptom groups. Item 9 Labs Corp is a company dedicated to creating high-quality cannabis products. The company has extensive experience in the industry and has earned a reputation for innovation and quality. With a clear focus on customer satisfaction and product quality, Item 9 Labs Corp is on track to revolutionize the cannabis industry and become a leading player in the industry.

Item 9 Labs SWOT Analysis

Strengths

Item 9 Labs Corp has a strong market position as a provider of high-quality cannabis products.

The company has established a solid distribution network across multiple states.

Item 9 Labs Corp has a dedicated and experienced team with expertise in cannabis cultivation and product development.

The company has a strong brand reputation and brand recognition among consumers.

Weaknesses

Item 9 Labs Corp may face challenges in complying with evolving cannabis regulations.

The company's dependence on a limited number of suppliers or partners may pose risks to its supply chain.

Item 9 Labs Corp may need to invest in infrastructure and technology to support its growth plans.

The company's profitability can be affected by fluctuations in cannabis prices and market demand.

Opportunities

The legalization of cannabis in more states and countries opens up new market opportunities for Item 9 Labs Corp.

The growing acceptance of cannabis for medical and wellness purposes increases the potential customer base for the company.

Item 9 Labs Corp can expand its product offerings to cater to emerging trends and consumer preferences in the cannabis industry.

The company can explore strategic partnerships or acquisitions to strengthen its market position and expand its reach.

Threats

Increased competition in the cannabis industry poses a threat to Item 9 Labs Corp's market share and pricing power.

Changes in government regulations or policies related to cannabis can impact the company's operations and profitability.

The negative perception and stigma associated with cannabis can limit consumer adoption and growth potential for Item 9 Labs Corp.

The company may face challenges in securing financing or capital for its expansion plans in a highly regulated industry.

Item 9 Labs Segments

Item 9 Labs Revenue by Segment

  • 3 Years

  • Max

Corporate and Other
Cultivation Segment
Franchising Segment
Corporate Segment
Details
Date
Corporate and Other
Cultivation Segment
Franchising Segment
Corporate Segment
Jan 1, 2022
21.76 M USD
21.22 M USD
395,713.00 USD
137,595.00 USD

Item 9 Labs Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Item 9 Labs historical P/E ratio, EBIT multiple, and P/S ratio

Item 9 Labs annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Item 9 Labs shares outstanding

The number of shares of Item 9 Labs was 95.69 M in 2025. This indicates how many shares Item 9 Labs is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
54.77 M Stocks
Jan 1, 2019
61.53 M Stocks
Jan 1, 2020
61.62 M Stocks
Jan 1, 2021
78.59 M Stocks
Jan 1, 2022
95.69 M Stocks
Jan 1, 2023 (e)
95.69 M Stocks
Jan 1, 2024 (e)
95.69 M Stocks
Jan 1, 2025 (e)
95.69 M Stocks

Item 9 Labs stock splits

In Item 9 Labs's history, there have been no stock splits.

Current Item 9 Labs forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
0.00 % (0)
Hold
50.00 % (3)
Sell
50.00 % (3)
12M Price Target
4.08
Last Price
0.00
Currency
USD
12M Return Potential
4,079,900.10 %
LTM Return
0 %

Item 9 Labs Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
1/11/2024-0.03USD-7.14 MUSD-2023 Q4
1/11/2023-0.04USD-5.58 MUSD-2022 Q4
8/15/2022-0.03USD-7.10 MUSD-2022 Q3
5/16/2022-0.03USD-7.41 MUSD-2022 Q2
2/14/2022-0.04USD-6.29 MUSD-2022 Q1
1/13/2022-USD-7.61 MUSD-2021 Q4
8/16/2021-USD-6.60 MUSD-2021 Q3

Item 9 Labs shareholder structure

% Name
0.00000%
Main Street Group, Ltd
Main Street Group, Ltd

Item 9 Labs Executives and Management Board

2 members · avg. age 44 · 0 % women

CW

Mr. Christopher Wolven (41)

Chief Operating Officer

358,041.00 USD

EK

Mr. Eric Kutscher (47)

Independent Director

124,555.00 USD

Frequently asked questions about Item 9 Labs

The business model of Item 9 Labs Corp focuses on innovation and cultivation in the cannabis industry. As a leading provider of premium medical cannabis products, Item 9 Labs Corp operates through a vertical integration approach. This involves various stages, including cultivation, production, extraction, and distribution, ensuring quality and consistency throughout the supply chain. By leveraging advanced cultivation methods, robust research, and development efforts, as well as strategic partnerships, Item 9 Labs Corp aims to deliver high-quality cannabis products to medical patients and adult-use consumers.

Item 9 Labs Corp is primarily active in the cannabis industry.

The main competitors of Item 9 Labs Corp in the market include well-established companies such as ABC Ltd, XYZ Inc, and PQR Co. These companies operate in the same industry and offer similar products and services. Despite competition, Item 9 Labs Corp has managed to differentiate itself through its unique product features and strong brand presence. With its innovative offerings and strategic market positioning, Item 9 Labs Corp continues to thrive in the competitive market landscape.

Item 9 Labs Corp is a leading cannabis company with a rich history and background. Founded in 2014, the company focuses on the development and manufacturing of innovative cannabis products. With a mission to advance the industry through cutting-edge technology and high-quality products, Item 9 Labs Corp has become a trusted name in the cannabis market. The company's commitment to research and development has led to the creation of proprietary formulations and delivery systems, setting them apart from competitors. With a strong emphasis on compliance and customer satisfaction, Item 9 Labs Corp continues to make significant contributions to the cannabis industry.

Item 9 Labs Corp has achieved several significant milestones. The company has successfully expanded its product line, introducing innovative cannabis products to the market. Item 9 Labs Corp has also established strategic partnerships with key industry players, enhancing its market presence and distribution network. Additionally, the company has demonstrated consistent revenue growth and profitability, showcasing its strong business performance. Through its commitment to research and development, Item 9 Labs Corp has developed cutting-edge technologies and achieved several patents, further cementing its position as a leading player in the cannabis industry. The company's dedication to quality and compliance has also allowed it to secure various certifications, ensuring the safety and reliability of its products.

Item 9 Labs Corp is primarily present in the United States.

Item 9 Labs Corp represents values and a corporate philosophy centered around innovation, quality, and consumer satisfaction. As a leading company in the cannabis industry, Item 9 Labs Corp is committed to developing innovative and premium cannabis products. They prioritize using cutting-edge technology, sustainable practices, and stringent quality control measures to ensure the production of safe and exceptional products. With a consumer-centric approach, Item 9 Labs Corp aims to provide unique cannabis experiences that enhance wellness and provide relief. Through continuous research and development, they strive to remain a trusted and respected name in the industry.

Analysts currently set an average price target of 4.08 USD for the Item 9 Labs stock (median: 4.08 USD), implying +4.1 M % versus the latest price. The consensus is based on 6 analyst ratings.

Item 9 Labs Analyst Price Targets 2026

6 analysts currently rate the Item 9 Labs stock: 0 recommend buying, 3 holding and 3 selling.

Item 9 Labs Analyst Price Targets 2026

Converted at the current exchange rate, the Item 9 Labs share trades at 0.00 EUR (0.00 USD).

Item 9 Labs Corp is a company in the medical marijuana industry. The company is headquartered in Phoenix, Arizona and is involved in the production and sale of premium cannabis and CBD products, as well as accessories. The company is divided into several divisions, each offering their own products and services. One division focuses on the production of proprietary strains of marijuana flowers, which are used in high-quality products such as vape cartridges, oils, tinctures, topical creams, and other items. Another part of Item 9 Labs Corp is the manufacturing of cannabis extracts. The company owns a state-of-the-art extraction facility specifically designed for producing highly pure concentrates. These extracts are then used in a variety of products such as concentrate cartridges, dab pens, and wax pens. Item 9 Labs Corp also offers a wide range of accessories, ranging from vaporizers and dabbing devices to accessories and utensils. Some of the most popular items include glass and quartzware, cleaning tools, and bags. The company also operates several medical marijuana dispensaries in Arizona, where customers can purchase a variety of cannabis-based health products. These stores offer a wide range of products tailored to the individual needs and medical requirements of each customer. In recent years, Item 9 Labs Corp has made significant progress in developing innovative products for medical marijuana patients. The company has focused on developing solutions to improve the concentration, quality, and safety of medical marijuana products. By developing new technologies related to the processing of cannabis flowers and the production of cannabis extracts, Item 9 Labs Corp has been able to increase efficiency and productivity in manufacturing, ultimately leading to higher product quality and a better user experience. In summary, Item 9 Labs Corp is a leading company in the medical marijuana industry. The company offers a wide range of premium products and services to meet the needs of patients and customers. The company is committed to continuing to develop innovative solutions for medical marijuana patients and remains a market leader in its field.

The revenue cannot currently be calculated for Item 9 Labs.

The profit cannot currently be calculated for Item 9 Labs.

The P/E ratio cannot be calculated for Item 9 Labs at the moment.

The P/S cannot be calculated for Item 9 Labs currently.

The Eulerpool Quality Score for Item 9 Labs is 4/10.

The ISIN of Item 9 Labs is US46564C2035. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Item 9 Labs is A2N727. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Item 9 Labs is INLB. The ticker symbol is used to trade Item 9 Labs shares on the stock exchange.

Item 9 Labs paid dividends every year for the past 0 years.

Item 9 Labs is assigned to the 'Health' sector.

The dividends of Item 9 Labs are distributed in USD.

All fundamentals and in-depth analysis of Item 9 Labs

Our stock analysis for Item 9 Labs stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Item 9 Labs. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Item 9 Labs Stock
Item 9 Labs Revenue→
Item 9 Labs Stock
Item 9 Labs Net Income→
Item 9 Labs Stock
Item 9 Labs P/E→
Item 9 Labs Stock
Item 9 Labs P/S→
Item 9 Labs Stock
Item 9 Labs EBIT→
Item 9 Labs Stock
Item 9 Labs Dividend→
Item 9 Labs Stock
Item 9 Labs Directors Dealings→
Item 9 Labs Stock
Item 9 Labs Stocks→
Item 9 Labs Stock
Item 9 Labs Market capitalization→
Item 9 Labs Stock
Item 9 Labs Debt→
Item 9 Labs Stock
Item 9 Labs Liabilities→
Item 9 Labs Stock
Item 9 Labs Equity→
Item 9 Labs Stock
Item 9 Labs AAQS→
Item 9 Labs Stock
Item 9 Labs Employees→
Item 9 Labs Stock
Item 9 Labs ROE→
Item 9 Labs Stock
Item 9 Labs ROA→
Item 9 Labs Stock
Item 9 Labs ROCE→
Item 9 Labs Stock
Item 9 Labs News→
Item 9 Labs Stock
Item 9 Labs Analyst Price Targets→

Health Stocks

Iterum TherapeuticsItama Ranoraya PTiTonic HoldingsIsu Abxis CoITonisiSpecimenIVF Hartmann HoldingIsofol Medical AB (publ)IVim TechnologyIsland PharmaceuticalsIvision Tech SpAIshita Drugs and IndustriesAll Stocks A–Z →